Invivo Therapeutics (NASDAQ:NVIV) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.03), Bloomberg Earnings reports.
Invivo Therapeutics stock traded down $0.01 during midday trading on Wednesday, hitting $0.62. The company’s stock had a trading volume of 7,935 shares, compared to its average volume of 68,122. Invivo Therapeutics has a 1-year low of $0.52 and a 1-year high of $2.75. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.86 and a current ratio of 6.86. The company has a 50-day simple moving average of $0.67. The company has a market capitalization of $5.80 million, a P/E ratio of -0.27 and a beta of 1.43.
Separately, ValuEngine cut shares of Invivo Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st.
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord.
Recommended Story: What is the QQQ ETF?
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.